For the latest updates on our ongoing response to COVID-19, please click here.

HIV/HCV NoCo Program

No Co-infection (NoCo) 2019: HCV Elimination in Specific Populations and Regions with High Prevalence or Risk of HIV and HCV Infection

Through Medical Affairs, Gilead Sciences supports the research efforts of academic institutions, clinical investigators, community organizations and research networks to help inform the scientific community about barriers and facilitators of HCV elimination, including micro-elimination in people living with HIV. Targeting micro-elimination of HCV in HIV-infected or high-risk HIV-uninfected individuals is a feasible and a more proximate short-term goal and a positive step toward more global HCV elimination.

Gilead will support projects with research grants of up to $600,000 each, with an emphasis on achieving geographic distribution across the globe. Successful proposals will demonstrate clear scientific objectives, defined timelines, a comprehensive operational plan and the potential to generate data that has relevance to the medical community and policy makers. See the below downloadable Request for Proposal (RFP) document for more information.

Key Dates & Program Specifics:

  • 27 June 2019: Letter of Intent (LOI) submission window opens
  • 9 August 2019: LOI submission window closes
  • LOI should be submitted to using the template provided below

Gilead plans to approve awards for these research proposals, dependent upon availability of funds and receipt of meritorious applications. Awards shall be for research purposes only.

Questions about the program or LOI process should be submitted to your local Gilead Medical Scientist or to

Downloadable Documents

NoCo 2019 RFP

NoCo 2019 LOI